Progression of mouse mammary tumors: MCP-1-TNFα cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors

International Journal of Cancer

Volumn 106, Issue 6, 2003, Pages 879-886

  Neumark, Eran ^a   Sagi Assif, Orit ^a   Shalmon, Bruria ^b   Ben Baruch, Adit ^a   Witz, Isaac P ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

IL 6; IP 10; Matrix metalloproteinases; MCP 1; TNF ; Tumor heterogeneity; Tumor microenvironment

Indexed keywords

CHEMOKINE; INTERLEUKIN 6; IP10 CHEMOKINE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CELL CLONE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION;

ACUTE DISEASE; ADENOCARCINOMA; ANIMALS; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOKINES, CXC; DISEASE PROGRESSION; FEMALE; GELATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LEUKEMIA; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MONOCYTES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0041337015     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11337     Document Type: Article

References (41)

1. Nicolson GL. Quantitative variations in gene expression: possible role in cellular diversification and tumor progression. J Cell Biochem 1991;46:277-83.
2. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
3. Witz IP. The tumour microenvironment: introduction. Semin Cancer Biol 2002;12:87-8.
4. Neumark E, Cohn MA, Lukanidin E, Witz IP, Ben-Baruch A. Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol Lett 2002;82:111-21.
5. Neumark E, Anavi R, Witz IP, Ben-Baruch A. MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunol Lett 1999;68:141-6.
6. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92:1085-91.
7. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6:3282-9.
8. Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999;82:765-70.
9. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998;194:335-40.
10. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34-40.
11. Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000;7:124-9.
12. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642-6.
13. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 2000;7:187-90.
14. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999;19:1427-32.
15. MacDougall JR, Matrisian LM. Matrix metalloproteinases in the pathogenesis of breast cancer. In: Bowcock AM, ed. Breast cancer: molecular genetics, pathogenesis and herapeutics. Totowa, NJ: Humana Press, 1999. 305-24.
16. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 2000;36:1258-68.
17. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 1998;50:97-116.
18. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001;70:478-90.
19. O'Sullivan C, Lewis CE. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 1994;172:229-35.
20. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
21. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
22. van Netten JP, Ashmed BJ, Cavers D, Fletcher C, Thornton IG, Antonsen BL, Coy P, Brigden ML. "Macrophages" and their putative significance in human breast cancer. Br J Cancer 1992;66:220-1.
23. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77:2246-51.
24. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994;56:777-82.
25. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997;43:211-5.
26. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8.
27. Sun H, Jackson MJ, Kundu N, Fulton AM. Interleukin-10 gene transfer activates interferon-gamma and the interferon-gamma-inducible genes Gbp-1/Mag-1 and Mig-1 in mammary tumors. Int J Cancer 1999;80:624-9.
28. Dorsey R, Kundu N, Yang Q, Tannenbaum CS, Sun H, Hamilton TA, Fulton AM. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 2002;62:2606-10.
29. Sun H, Kundu N, Dorsey R, Jackson MJ, Fulton AM. Expression of the chemokines IP-10 and Mig in IL-10 transduced tumors. J Immunother 2001;24:138-43.
30. Luster AD, Leder P. IP-10, a-C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65.
31. Fu YX, Watson G, Jimenez JJ, Wang Y, Lopez DM. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990;50:227-34.
32. Barendsen N, Mueller M, Chen B. Inhibition of TPA-induced monocytic differentiation in THP-1 human monocytic leukemic cells by staurosporine, a potent protein kinase C inhibitor. Leuk Res 1990;14:467-74.
33. Cochran FR, Finch-Arietta MB. Regulation of interleukin-1 beta and tumor necrosis factor secretion by the human monocytic leukemia cell line, THP-1. Agents Actions 1989;27:271-3.
34. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000;85:182-8.
35. Baqui AA, Meiller TF, Chon JJ, Turng BF, Falkler WA Jr. Granulocyte-macrophage colony-stimulating factor amplification of interleukin-1beta and tumor necrosis factor alpha production in THP-1 human monocytic cells stimulated with lipopolysaccharide of oral microorganisms. Clin Diagn Lab Immunol 1998;5:341-7.
36. Heppner GH. Tumor heterogeneity. Cancer Res 1984;44:2259-65.
37. Nicolson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 1987;47:1473-87.
38. Nowell PC. Mechanisms of tumor progression. Cancer Res 1986;46:2203-7.
39. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
40. Berko-Flint Y, Fridman WH, Grossman-Atlas E, Kimchi N, Ben-Baruch AL, Moss S, Teillaud JL, Witz IP, Ran M. Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. Mol Immunol 1990;27:1219-28.
41. Gonen B, Ran M, Wreschner D, Cahalon L, Anavi R, Shlomo Y, Witz IP. Some immunological properties of high and low tumorigenic cellular variants of c-H-ras transformed 3T3 cells. Nat Immun Cell Growth Regul 1988;7:144-54.